About US
Contact us
-
US FDA grants Fast Track Designation to Novavax’s RSV F VaccineThe US Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax's respiratory syncytial virus (RSV) F-Protein nanoparticle vaccine candidate (RSV F Vaccine) that can be used to2016/5/30
-
US FDA's EMDAC recommends approval of Sanofi’s NDA to treat type II diabetesThe US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has recommended the approval for French-based Sanofi's New Drug Application (NDA) to treat typ2016/5/27
-
UK CRT and Pangaea Biotech to develop new drugs to treat cancerUK's Cancer Research Technology (CRT) has signed a licence agreement with Spanish company Pangaea Biotech, to develop p21-activated kinase (PAK) inhibitor drugs to treat cancer. Scientists at CRT's D2016/5/27
-
Novartis establishes new global clinical programme of Entresto and heart failureSwiss pharmaceutical company Novartis has established a global clinical programme, Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy), to address the heart failure disea2016/5/26
-
Deals this week: Trianni, ANI Pharma, Merus LabsTrianni and Evotec AGhave entered a co-development agreement to develop Evotec's existing drug discovery platforms, as well as new projects. The agreement enables Evotec to gain access to the Trianni2016/5/26
-
CGT and Aberdeen University establish new company for diabetes treatmentUK-based cell and gene therapy industry Cell and Gene Therapy Catapult (CGT), along with the University of Aberdeen, has announced the establishment of new company Islexa. Islexa is set-up to develop2016/5/25
-
M&As this week: Strides Shasun and Shanghai Fosun PharmaStrides Shasunhas announced plans to sell Shasun Pharma to its current management, a provider of contract research and manufacturing services in the UK. The sale consideration is expected to be appro2016/5/25
-
NICE approves GSK's lupus drug BenlystaThe National Institute for Health and Care Excellence (NICE) has reportedly approved GlaxoSmithKline's (GSK) Benlysta for the treatment of lupus. Earlier in 2011, NICE rejected Benlysta as it believe2016/5/24
-
Merck's Keytruda gets FDA breakthrough therapy designation for cHLMerck, commonly known as MSD, has obtained breakthrough therapy designation from the US Food and Drug Administration (FDA) for its Keytruda (pembrolizumab) to treat patients with relapsed or refractor2016/5/23
-
NICE recommends PTC's Translarna to treat Duchenne muscular dystrophyThe UK's National Institute for Health and Care Excellence (NICE) has recommended PTC Therapeutics' Translarna (ataluren) for the treatment of Duchenne muscular dystrophy (DMD) caused by a nonsense mu2016/5/23